Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

NCT06182774 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

570

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Isatuximab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]